By a News Reporter-Staff News Editor at Health & Medicine Week -- Fresh data on Enzymes and Coenzymes are presented in a new report. According to news originating from Marseille, France, by NewsRx correspondents, research stated, "The aim of this study was to develop poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) for delivery of a protein-tissue inhibitor of matrix metalloproteinases 1 (TIMP-1)-across the blood-brain barrier (BBB) to inhibit deleterious matrix metalloproteinases (MMPs). The NPs were formulated by multiple-emulsion solvent-evaporation, and for enhancing BBB penetration, they were coated with polysorbate 80 (Ps80)."
Our news journalists obtained a quote from the research from Aix-Marseille University, "We compared Ps80-coated and uncoated NPs for their toxicity, binding, and BBB penetration on primary rat brain capillary endothelial cell cultures and the rat brain endothelial 4 cell line. These studies were followed by in vivo studies for brain delivery of these NPs. Results showed that neither Ps80-coated nor uncoated NPs caused significant opening of the BBB, and essentially they were nontoxic. NPs without Ps80 coating had more binding to endothelial cells compared to Ps80-coated NPs. Penetration studies showed that TIMP-1 NPs + Ps80 had 11.21%+/-1.35% penetration, whereas TIMP-1 alone and TIMP-1 NPs without Ps80 coating did not cross the endothelial monolayer. In vivo studies indicated BBB penetration of intravenously injected TIMP-1 NPs + Ps80."
According to the news editors, the research concluded: "The study demonstrated that Ps80 coating of NPs does not cause significant toxic effects to endothelial cells and that it can be used to enhance the delivery of protein across endothelial cell barriers, both in vitro and in vivo."
For more information on this research see: Tissue inhibitor of matrix metalloproteinases-l loaded poly(lactic-co-glycolic acid) nanoparticles for delivery across the blood-brain barrier. International Journal of Nanomedicine, 2014;9():575-588. International Journal of Nanomedicine can be contacted at: Dove Medical Press Ltd, PO Box 300-008, Albany, Auckland 0752, New Zealand (see also Enzymes and Coenzymes).
The news correspondents report that additional information may be obtained from M. Chaturvedi, Aix Marseille Univ, CNRS, NICN, UMR7259, Marseille, France. Additional authors for this research include Y. Molino, B. Sreedhar, M. Khrestchatisky and L. Kaczmarek.
Keywords for this news article include: France, Europe, Marseille, Proteomics, Nanoparticle, Nanotechnology, Peptide Hydrolases, Blood Brain Barrier, Blood-Brain Barrier, Emerging Technologies, Enzymes and Coenzymes, Metalloendopeptidases, Matrix Metalloproteinases
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC